Personalized Mast Cell Profiling and AI-Driven Treatment Optimization for BPH Management

A next-generation approach to treating benign prostatic hyperplasia (BPH) by integrating personalized mast cell profiling, histamine receptor antagonist response, and machine learning-based treatment optimization to provide more effective and targeted therapies.

The original patent disclosed combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist for treating BPH. However, these treatments often lack personalization, leading to variable efficacy and potential side effects. The new inventive concept addresses these limitations by incorporating advanced profiling and AI-driven analytics to tailor treatment to individual patients' needs.

The inventive concept comprises a personalized mast cell profiling module, which uses biomarkers and machine learning algorithms to identify specific mast cell patterns associated with BPH. The system also includes a histamine receptor antagonist module, which selects the most effective antagonist based on the patient's profile. A machine learning-based treatment optimization module then analyzes the patient's response to the treatment and adjusts the therapy accordingly. The system can be integrated with wearable devices, cloud-based platforms, and biofeedback systems to provide real-time monitoring and treatment recommendations.

The new claims introduce a paradigm shift in BPH treatment by incorporating personalized profiling, AI-driven analytics, and machine learning-based optimization. These advancements provide a significant improvement over the original patent's combination therapies, enabling more targeted and effective treatment of BPH.

Alternative embodiments of the inventive concept could include using different biomarkers or machine learning algorithms for profiling, incorporating additional therapeutic agents or modalities, or developing specialized platforms for specific patient populations. Variations could also involve integrating the system with electronic health records, telemedicine platforms, or other healthcare technologies.

The inventive concept has significant commercial potential in the BPH treatment market, which is projected to grow substantially in the coming years. The system's ability to provide personalized and targeted therapies could lead to improved treatment outcomes, reduced healthcare costs, and increased patient satisfaction. The market for this technology could include pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve BPH treatment options.